论文部分内容阅读
氟布洛芬是一种新型非甾体类抗炎药,能有效地抑制前列腺素合成酶,从而抑制前列腺素的生物合成,达到缓解痛经的目的。但对氟布洛芬治疗痛经疗效报道不一,作者进一步作了研究。病例选择与研究方法:受试对象为87名(年龄在16～39岁,平均24.9岁,且无肝、肾疾病,无消化性溃疡、哮喘病及骨盆畸形)患严重痛经且已治疗6个月以上未缓解者。受试者在连续三个痛经期内,按药物编号随机分为三组:(1)19名患者在第一周期服50mg 氟布洛芬,第二周期服650mg 阿司匹林,第三周期服安慰剂;(2)21名患者在第一周期服阿司匹林,第二周期服安慰剂,第三周期服氟布洛芬;(3)19名患者第一周期服安慰剂,第二周期服氟布洛芬,
Flurbiprofen is a new non-steroidal anti-inflammatory drugs, can effectively inhibit prostaglandin synthase, thereby inhibiting prostaglandin biosynthesis, to alleviate the purpose of dysmenorrhea. However, the efficacy of flurbiprofen in the treatment of dysmenorrhea reported differently, the author further studied. Case Selection and Study Methods: Subjects were 87 (16-39 years old with an average of 24.9 years old and without liver, kidney disease, peptic ulcer, asthma and pelvic deformity) suffering from severe dysmenorrhea and have been treated 6 Month or more who did not ease. Subjects were randomized to three groups according to drug numbers for three consecutive menstrual periods: (1) 19 patients received fenoborphine 50 mg in the first cycle, aspirin 650 mg in the second cycle, and placebo in the third cycle ; (2) 21 patients received aspirin in the first cycle, placebo in the second cycle, and fluvastipin in the third cycle; (3) 19 patients received placebo in the first cycle and Fluor Fen,